IVYLAND, PA — LifeLens Technologies has received expanded U.S. Food and Drug Administration 510(k) clearance for its wearable physiological monitoring platform, broadening the range of clinical measurements the device can provide as healthcare providers increasingly adopt continuous patient monitoring technologies.
The clearance adds blood oxygen saturation (SpO2), heart rate, respiration rate, heart rate variability, skin temperature and wellness metrics—including activity, body position, step count and gait analysis—to the platform’s previously cleared electrocardiogram (ECG) monitoring capabilities, the company stated.
The expanded authorization allows LifeLens to market a single wearable system capable of capturing multiple physiological measurements that are commonly used to monitor patients in clinical settings. The company positions the platform as a tool to improve access to continuous patient data while addressing concerns over data reliability and clinical confidence.
“Managing complex disease requires monitoring solutions that deliver the breadth of clinical, environmental, and contextual data needed to make informed treatment decisions,” founder and Chief Executive Officer Landy Toth said. “But breadth alone isn’t enough, the data has to be trusted.”
Toth added that the FDA clearance, together with ongoing clinical studies, is intended to strengthen the evidence supporting the platform’s use in clinical decision-making.
The company also cited ongoing validation efforts through multiple clinical studies that are currently enrolling participants, though it did not disclose details on the studies or expected completion dates.
Robert Schwartz, medical director for LifeLens and a physician affiliated with the Minneapolis Heart Institute Foundation, described the clearance as validation of the technology’s “accuracy, safety, and clinical applicability” and said it supports broader clinical use of the platform.
LifeLens reported that the technology underlying its monitoring system has been evaluated by the U.S. military since 2021 in more than 50 field exercises. According to the company, those deployments have been used to monitor vital signs, assess heat- and musculoskeletal injury risks, and evaluate unit readiness during training and operational activities.
The company plans to apply lessons from those military deployments as it expands the platform’s use in civilian healthcare.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.